Pharmacologic and radiotherapeutic interventions for advanced pancreatic cancer

The primary objective is to conduct a systematic review of the published and unpublished literature to assess the effect of chemotherapy, radiotherapy and biological therapies, either alone or in combination, on overall survival in people with advanced pancreatic carcinoma.

We will examine these effects:

  1. in the setting of inoperable advanced (including locally advanced and metastatic) or relapsed disease;
  2. in the setting of first line or second line treatment. 

Adverse effects and quality of life data (where available) will be recorded and tabulated.

Comparisons will be as follows.

  1. Any chemotherapy treatment versus placebo or no treatment or best supportive care.
  2. Any chemotherapy treatment versus any chemotherapy treatment.
  3. Any biological agent versus placebo or no treatment or best supportive care.
  4. Any biological agent versus any biological agent.
  5. Any biological agent combined with any chemotherapy treatment versus no treatment or best supportive care.
  6. Any biological agent combined with any chemotherapy treatment versus any chemotherapy treatment.
  7. Any biological agent combined with any chemotherapy treatment versus any biological agent combined with any chemotherapy treatment.
  8. Any radiotherapy treatment versus placebo or no treatment or best supportive care.
  9. Any radiotherapy treatment versus any radiotherapy treatment.
  10. Any combination of radiotherapy and chemotherapy versus placebo, no treatment or best supportive care.
  11. Any combination of radiotherapy and chemotherapy versus any combination of radiotherapy and chemotherapy.
  12. Any combination of radiotherapy and biological agent versus placebo, no treatment or best supportive care.
  13. Any combination of radiotherapy and biological agent versus any combination of radiotherapy and biological agent.
  14. Any combination of radiotherapy and chemotherapy treatment and biological agent versus placebo, no treatment or best supportive care.
  15. Any combination of radiotherapy and chemotherapy treatment and biological agent versus any combination of radiotherapy and chemotherapy and biological agent.

This is a protocol.

Share/Save